GSK receives positive CHMP opinion in Europe for StrimvelisTM, the first gene therapy to treat very rare disease, ADA-SCID
We would like to congratulate the teams at TIGET and at GSK for this wonderful news and look forward to hearing more about it during the session dedicated to ADA-SCID at the ESGCT congress which will take place in Florence from 18 to 21 october. For more information on the congress you can go to the ESGCT website congress page
The gene therapy for the treatment of ADA-SCID was originally developed by Ospedale San Raffaele (OSR) and Fondazione Telethon (Telethon), through their joint San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) and was taken forward by GSK through a strategic collaboration formed in 2010 read more....
Press release from GSK
?Press release from EMA